Asia-Pacific Inhaler Market Size, Share & Trends Analysis Report by Device (Metered Dose Inhaler, Dry Powdered Inhaler, and Nebulizer), by Type (Preventive Inhaler, Reliever Inhaler, and Long Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.
Asia-Pacific inhaler market is anticipated to grow at a substantial rate of 4.1% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in life science research coupled with harnessing innovation. The inhaler market in Asia-Pacific region presents future opportunities for growth as prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing geriatric population specially in Japan is another major reason for growing market.
The Asia-Pacific inhaler market is segmented on the basis of device, type, application, and end-user. On the basis of device, the market is sub-segmented into metered dosed inhaler, dry powdered inhaler, and nebulizer. The dry powder inhaler is estimated to have largest market share in the Asia-Pacific inhaler market due to providing easy inhalation solution. Based on the type, preventive, reliever, and long acting bronchodilators inhaler are analyzed. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing inhaler to cater to a wide range of customers within the region and across the globe. The major players of the Asia-Pacific inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, Propeller Health, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access of life-changing medicines in India.
Research Methodology
The market study of the Asia-Pacific inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.
Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.
Secondary Sources Include
Market Segmentation
1. Asia-Pacific Inhaler Market Research and Analysis by Device
2. Asia-Pacific Inhaler Market Research and Analysis by Type
3. Asia-Pacific Inhaler Market Research and Analysis by Application
4. Asia-Pacific Inhaler Market Research and Analysis by End-User
The Report Covers
Asia-Pacific inhaler market is anticipated to grow at a substantial rate of 4.1% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in life science research coupled with harnessing innovation. The inhaler market in Asia-Pacific region presents future opportunities for growth as prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing geriatric population specially in Japan is another major reason for growing market.
The Asia-Pacific inhaler market is segmented on the basis of device, type, application, and end-user. On the basis of device, the market is sub-segmented into metered dosed inhaler, dry powdered inhaler, and nebulizer. The dry powder inhaler is estimated to have largest market share in the Asia-Pacific inhaler market due to providing easy inhalation solution. Based on the type, preventive, reliever, and long acting bronchodilators inhaler are analyzed. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing inhaler to cater to a wide range of customers within the region and across the globe. The major players of the Asia-Pacific inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, Propeller Health, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access of life-changing medicines in India.
Research Methodology
The market study of the Asia-Pacific inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.
Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.
Secondary Sources Include
- Financial reports of companies involved in the market
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalog
Market Segmentation
1. Asia-Pacific Inhaler Market Research and Analysis by Device
2. Asia-Pacific Inhaler Market Research and Analysis by Type
3. Asia-Pacific Inhaler Market Research and Analysis by Application
4. Asia-Pacific Inhaler Market Research and Analysis by End-User
The Report Covers
- Comprehensive research methodology of the Asia-Pacific inhaler market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Asia-Pacific inhaler market.
- Insights about market determinants which are stimulating the Asia-Pacific inhaler market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- Aradigm Corp.
- AstraZeneca PLC
- Beximo Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- GlaxoSmithKline PLC
- Koninklijke Philips N.V.
- MidasCare Pharmaceutical Pvt. Ltd.
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Sunovion Pharmaceuticals
- Teijin Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
